Signaling and Biotechology Program

信号传导和生物技术计划

基本信息

批准号：
10093001
负责人：
Hui-Kuan Lin
金额：
$ 3.48万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-02-01 至 2022-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10093001
关键词：
3-Dimensional Address Agonist Animal Model Antibodies Antibody Formation Architecture Area Ascites Automobile Driving B-Lymphocytes Baptist Church Basic Cancer Research Biochemical Bioinformatics Biological Biological Process Biology Biometry Biophysics Biotechnology Breast Cancer therapy C Type Lectin Receptors CD4 Positive T Lymphocytes CHD7 gene Cancer Center Support Grant Cancer Detection Carcinomatosis Catchment Area Cause of Death Cell Culture Techniques Cell Lineage Cells Certification Clinic Clinical Clinical Medicine Clinical Research Clinical Trials Collaborations Communication Complex Comprehensive Cancer Center Computer Models Contrast Media DNA Damage DNA Repair Detection Development Devices Diagnosis Discipline Disease Disease Progression Dose Drug Kinetics Drug resistance Effectiveness Effector Cell Electromagnetic Fields Engineering Environment European Excision FOLH1 gene Flow Cytometry Flow Cytometry Shared Resource Genetic Screening Goals Growth Guidelines Hematopoietic stem cells Hemoglobin Heterogeneity Human Hypoxia Image Imaging Device Immune system Immunotherapeutic agent In Vitro Incidence Institutes Knowledge Laboratories Link Lipid A Liver X Receptor Localized Malignant Neoplasm Malignant Neoplasms Malignant neoplasm of abdomen Malignant neoplasm of prostate Mammary Neoplasms Mass Spectrum Analysis Measurement Measures Mechanics Mediating Medical Medical Device Metastatic malignant neoplasm to brain Methodology MicroRNAs Microfluidic Microchips Mitochondrial Proteins Modality Modeling Monitor Mus Nature Neoadjuvant Therapy Neoplasm Metastasis New Agents Non-Malignant Oncogenes Operating Rooms Operative Surgical Procedures Organ Organoids PINK1 gene Pathogenesis Pathway Analysis Pathway interactions Patients Peritoneal Pharmaceutical Preparations Phase Primary carcinoma of the liver cells Proteins Proteomics Protocols documentation RNA Radiosurgery Regenerative Medicine Regulation Reporting Reproduction Research Research Personnel Resistance Resolution Resource Sharing Retinoic Acid Receptor Review Committee Risk Role Sampling Saturated Fatty Acids Seminal Signal Pathway Signal Transduction Signaling Molecule Silicon Dioxide System T-Lymphocyte T-Lymphocyte Subsets TP53 gene TRAF6 gene Technology Testing Th1 Cells The Sun Therapeutic Therapeutic Intervention Time Tissues Tn antigen Toll-like receptors Transcription Coactivator Transforming Growth Factor beta Transgenic Mice Translating Treatment Efficacy Trehalose Tumor Antigens Tumor Markers Tumor Oxygenation Tumor Pathology Tumor Suppression Tumor Tissue Ubiquitination United States Work advanced prostate cancer aptamer base cancer cell cancer diagnosis cancer immunotherapy cancer initiation cancer therapy carbonate dehydratase castration resistant prostate cancer cell killing cellular engineering cellular imaging clinical translation computerized tools contrast enhanced deep learning algorithm diagnostic biomarker dimethylbenzanthracene epigenetic regulation exosome extracellular forest high throughput screening human disease imaging modality immune checkpoint improved in vivo individualized medicine innovation innovative technologies insight instrument interest mathematical model melanoma member metabolomics mitochondrial autophagy mortality mouse model multidisciplinary nanoparticle nanopore neoplastic cell new technology non-invasive imaging novel novel diagnostics novel therapeutics optoacoustic tomography overexpression pancreatic neoplasm particle patient response pharmacokinetic model physical science placental stem cell pre-clinical programs prostate cancer cell prostate cancer progression radio frequency refractory cancer relating to nervous system response senescence small molecule inhibitor stem cell expansion stem cell therapy stem cells theranostics therapeutic target therapy development therapy resistant treatment response triple-negative invasive breast carcinoma tumor tumor growth tumor hypoxia tumor immunology tumor microenvironment tumor progression tumor specificity tumorigenesis uptake

项目摘要

The major goals of the newly formed Signaling and Biotechnology (SBT) Program are to understand the mechanisms underlying cancer pathogenesis and resistance to therapy and to use this knowledge to develop new technologies leading to more effective strategies for improved detection and treatment of cancer. The SBT program combines a range of disciplines (signaling biology and therapeutics, engineering, clinical medicine, and physical sciences) with the goal of increasing basic knowledge and developing innovative technologies for research, diagnosis, and treatment of cancer. We focus on difficult-to-treat cancers and those with high incidence and mortality in the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) catchment area.

新形成的信号传导和生物技术（SBT）计划的主要目标是了解癌症发病机理和对治疗的抵抗力的机制，并利用这些知识发展新技术导致更有效的策略，以改善癌症的检测和治疗。 SBT 计划结合了一系列学科（信号生物学和治疗学，工程，临床医学，和物理科学）的目的是增加基础知识并开发创新技术癌症的研究，诊断和治疗。我们专注于难以治疗的癌症和较高的癌症 Wake Forest Baptist综合癌症中心（WFBCCC）集水区的发病率和死亡率。